Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

ÀڱðæºÎ¾ÏÀÇ ¼ö¼ú ÈÄ ¹æ»ç¼±Ä¡·á Adjuvant Postoperative Radiation Therapy for Carcinoma of the Uterine Cervix

´ëÇѹæ»ç¼±Á¾¾çÇÐȸÁö 2003³â 21±Ç 3È£ p.199 ~ 206
¼Ò¼Ó »ó¼¼Á¤º¸
ÀÌ°æÀÚ/LEE KJ ¹®Çý¼º/±è½Âö/±èÁ¾ÀÏ/¾ÈÁ¤ÀÚ/Moon HS/Kim SC/Kim CI/Ahn JJ

Abstract

¸ñÀû:ÀڱðæºÎ¾Ï¿¡¼­ ¼ö¼ú ÈÄ À§ÇèÀÎÀÚ°¡ Àִ ȯÀÚ¿¡ ¹æ»ç¼±Ä¡·á ÈÄ, »ýÁ¸À², ±¹¼Ò Á¦¾îÀ²°ú ¿¹ÈÄÀÎÀÚ¸¦ ÈÄÇâÀûÀ¸·Î ºÐ¼®ÇÏ¿© ¼ö¼ú ÈÄ ¹æ»ç¼±Ä¡·áÀÇ È¿°ú¸¦ ¾Ë°íÀÚ ÇÑ´Ù.
´ë»ó ¹× ¹æ¹ý: 1986³â 3¿ùºÎÅÍ 1998³â 12¿ù±îÁö ÀڱðæºÎ¾Ï FIGO º´±â IB-IIB·Î ÀÚ±ÃÀûÃâ¼ú ÈÄ ¹æ»ç¼±Ä¡·á¸¦ ¹ÞÀº 58¸íÀ» ´ë»óÀ¸·Î ±¹¼Ò Á¦¾îÀ², 5³â ¹«º´»ýÁ¸À²°ú »ýÁ¸À²¿¡ ¹ÌÄ¡´Â ¿¹ÈÄÀÎÀÚ¸¦ ÈÄÇâÀûÀ¸·Î ºÐ¼®ÇÏ¿´´Ù. ¼ö¼ú ÈÄ ¹æ»ç¼±Ä¡·áÀÇ ÀûÀÀÁõÀº º´¸®ÇÐÀûÀ¸·Î ¸²ÇÁÀý¿¡ ÀüÀÌµÈ °æ¿ì, ¾ÏÀÌ ¼ö¼úÀýÁ¦¿¬À̳ª, ÀÚ±ÃÁÖÀ§Á¶Á÷ ȤÀº ÀÚ±ÃüºÎ¿¡ ħ¹üÇÏ¿´°Å³ª, ¸²ÇÁÇ÷°ü°­¿¡ ħ¹üµÈ °æ¿ì, ÀڱñâÁúÀÇ 1/2 ÀÌ»ó ±íÀÌ Ä§À±µÈ °æ¿ì¿Í ´Ü¼ø ÀÚ±ÃÀûÃâ¼ú ÈÄ ¾ÏÀ¸·Î Áø´Ü¹ÞÀº ȯÀÚ·Î ÇÏ¿´´Ù. ¼ö¼ú ÈÄ ¹æ»ç¼±Ä¡·á´Â ¸ðµç ȯÀÚ¿¡¼­ °ñ¹Ý°­¿¡ ¿ÜºÎÁ¶»ç¸¦ ½ÃÇàÇÏ¿´À¸¸ç 5¸íÀº ¿ÜºÎÁ¶»ç¿Í °­³»Á¶»ç¸¦ º´¿ëÇÏ¿´´Ù. ¿ÜºÎÁ¶»ç´Â 6 MV x-¼±À» ÀÌ¿ëÇÏ¿© ¸ÅÀÏ 180 cGy¸¦ 4¹®À¸·Î Á¶»çÇÏ¿´À¸¸ç ÃÑ ¹æ»ç¼±·®Àº 4400 ~ 5040 cGy(Áß¾Ó°ª; 5040 cGy)À̾ú´Ù. °­³»Á¶»ç´Â ¿ÜºÎÁ¶»ç ÈÄ 2ÁÖ¿¡ Cs-137¸¦ ÀÌ¿ëÇÏ¿© Àú¼±·®·ü·Î Áú Ç¥¸é¿¡¼­ 5mm ±íÀÌ¿¡ 4488~4932 cGy¸¦ ½ÃÇàÇÏ¿´´Ù. ÃßÀû±â°£Àº 15°³¿ù¿¡¼­ 108°³¿ù·Î Áß¾Ó°ªÀº 44°³¿ùÀ̾ú´Ù.
°á°ú: ÀüüȯÀÚÀÇ 5³â ¹«º´»ýÁ¸À²Àº 94%, ±¹¼Ò Á¦¾îÀ²Àº 98%À̾úÀ¸¸ç ¿ø°Ý ÀüÀÌÀ²Àº 5%À̾ú´Ù. º´±â¿¡ µû¸¥ 5³â ¹«º´»ýÁ¸À²Àº IB 97.1%, IIA 100%, IIB 68.9% (p=0.0145)À̾ú´Ù. Áú ÀýÁ¦¿¬¿¡ ¾ÏÀÇ Ä§¹üÀÌ ¾ø´Â °æ¿ì 5³â ¹«º´»ýÁ¸À²ÀÌ 97.8%, ÀÖ´Â °æ¿ì 60% (p=0.0002)À̾úÀ¸¸ç, ÀÚ±ÃÁÖÀ§Á¶Á÷¿¡ ¾ÏÀÌ Ä§¹üÀÌ ¾ø´Â °æ¿ìÀÇ 5³â ¹«º´»ýÁ¸À²Àº 97.8%À̾ú°í, ÀÖ´Â °æ¿ì´Â 33.3%À̾ú´Ù(p=0.0001). ´Ùº¯·® ºÐ¼®¿¡ ÀÇÇϸé ÀÚ±ÃÁÖÀ§Á¶Á÷ÀÇ Ä§¹ü¸¸ÀÌ Åë°èÇÐÀûÀ¸·Î ÀÇÀÇÀÖ´Â ¿¹ÈÄÀÎÀÚÀ̾ú´Ù. Ä¡·á ÈÄ ¸¸¼ºÇÕº´ÁõÀº 3¸í(5%)¿¡¼­ RTOG grade 2ÀÇ ¹æ±¤¿°, 1¸í¿¡¼­ grade 2ÀÇ Á÷Àå¿°°ú 1¸í¿¡¼­ ÇÏÁö¿¡ ¸²ÇÁºÎÁ¾ÀÌ ³ªÅ¸³µ´Ù.
°á·Ð: Á¶±â ÀڱðæºÎ¾Ï ȯÀÚ¿¡ ´Ü¼ø ÀÚ±ÃÀûÃâ¼úÀ» ½ÃÇàÇÏ¿´°Å³ª, ±ÙÄ¡Àû ÀÚ±ÃÀûÃâ¼ú ÈÄ º´¸®ÇÐÀûÀ¸·Î Àç¹ß À§ÇèÀÎÀÚ°¡ Àִ ȯÀÚ¿¡ ¼ö¼ú ÈÄ ¹æ»ç¼±Ä¡·á¸¦ ½ÃÇàÇÏ¿© ½É°¢ÇÑ ºÎÀÛ¿ë ¾øÀÌ ºñ±³Àû ³ôÀº ±¹¼Ò Á¦¾îÀ²°ú »ýÁ¸À²À» ¾òÀ» ¼ö ÀÖ¾ú´Ù. »ýÁ¸À²¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ¿¹ÈÄÀÎÀÚ´Â º´¸®ÇÐÀûÀ¸·Î ¾ÏÀÌ ÀÚ±ÃÁÖÀ§Á¶Á÷¿¡ ħ¹üµÈ °ÍÀ¸·Î ¿¹ÈÄ°¡ ºÒ·®ÇÏ¿´´Ù. ¼ö¼ú ÈÄ ¹æ»ç¼±Ä¡·áÀÇ ½ÇÆпøÀΰú ¿¹ÈÄÀÎÀÚ¸¦ ºÐ¼®ÇÑ º» ÈÄÇâÀû ¿¬±¸°á°ú¸¦ Åä´ë·Î ¾ÕÀ¸·Î ¹æ»ç¼±Ä¡·á¿Í Ç×¾ÏÈ­Çпä¹ýÀ» º´¿ëÇÏ¿© º¸´Ù Àû±ØÀûÀÌ°í ÀüÇâÀûÀÎ ¿¬±¸¸¦ ½ÃµµÇϴµ¥ ÀÌÁ¤Ç¥·Î ÀÌ¿ëÇÒ ¼ö ÀÖ´Ù°í »ý°¢ÇÑ´Ù.


Purpose: This study was undertaken to evaluate the efficacy of postoperative radiotherapy, and to investigate the prognostic factors for FIGO stages IB-IIB cervical cancer patients who were treated with simple hysterectomy, or who had high-risk factors following radical hysterectomy and pelvic lymph node dissection.
Materials and methods: Between March 1986 and December 1998, 58 patients, with FIGO stages IB-IIB cervical cancer were included in this study. The indications for postoperative radiation therapy were based on the pathological findings, including lymph node metastasis, positive surgical margin, parametrial extension, lymphovascular invasion, invasion of more than half the cervical stroma, uterine extension and the incidental finding of cervix cancer following simple hysterectomy. All patients received external pelvic radiotherapy, and 5 patients, received an additional intracavitary radiation therapy. The radiation dose from the external beam to the whole pelvis was 45~50 Gy.Vagina cuff irradiation was performed, after completion of the external beam irradiation, at a low-dose rate of Cs-137, with the total dose of 4488~4932 chy (median : 4500 chy) at 5 mm depth from the vagina surface. The median follow-up period was 44 months (15~108 months).
Results: The 5-yr actuarial local control rate, distant free survival and disease-free survival rate were 98%, 95% and 94%, respectively. A univariate analysis of the clinical and pathological parameters revealed that the clinical stage (p=0.0145), status of vaginal resection margin (p=0.0002) and parametrial extention (p=0.0001) affected the disease-free survival. From multivariate analysis, only a parametrial extension independently influenced the disease-free survival. Five patients (9%) experienced Grade 2 rate treatment-related complications, such as radiation proctitis (1 patient), cystitis (3 patients) and lymphedema of the leg (1 patient). No patient had grade 3 or 4 complications.
Conclusion: Our results indicate that postoperative radiation therapy can achieve good local control and survival rates for patients with stages IB-IIB cervical cancer, treated with a simple hysterectomy, as well ass for those treated with a radical hysterectomy, and with unfavorable pathological findings. The prognostic factor for disease-free survival was invasion of the parametrium. The prognostic factor identified in this study for treatment failure can be used as a selection criterion for the combined treatment of radiation and chemotherapy.

Å°¿öµå

ÀڱðæºÎ¾Ï; ¼ö¼ú; ¹æ»ç¼±Ä¡·á;Cervix cancer;Surgery;Radiotherapy

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS